Moreover, Kreiter et al. have also shown that CD4+ response is crucial for effective anti-B16 immunity in mice after vaccination with tumor antigens, while CD8+ cells can be depleted without a noticeable effect on tumor rejection [18]. The gene discussed is CD8A; the disease is neoplasm.